Nanjing Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Nanjing Pharmaceutical Company Limited with three other
companies in this sector in China:
Shanghai Fosun Pharmaceutical (Group) Company Limited
sales of 14.51 billion Chinese Renmimbi [US$2.21 billion]
of which 70%
was Pharmaceutical Manufacturing and R&D),
Guangzhou Baiyunshan Pharmceutical Holdings Co Ltd
(20.03 billion Chinese Renmimbi [US$3.05 billion]
of which 39%
was Health), and
Sichuan Languang Development Co Ltd
(19.95 billion Chinese Renmimbi [US$3.04 billion]
of which 102%
was Real Estate Development & Management).
Nanjing Pharmaceutical Company Limited reported sales of 26.72 billion Chinese Renmimbi (US$4.06 billion)
December of 2016.
increase of 7.7%
versus 2015, when the company's sales were 24.81 billion Chinese Renmimbi.
Sales at Nanjing Pharmaceutical Company Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 56%).
Sales of Third-Part Logistics saw an increase
that was more than double the company's growth rate: sales were up
81.4% in 2016, from
3.66 million Chinese Renmimbi to 6.64 million Chinese Renmimbi.
Nanjing Pharmaceutical Company Limited also saw significant increases in sales in
E-Business (up 71.4% to 93.24 million Chinese Renmimbi)